Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

906.70
-10.8000-1.18%
Post-market: 911.474.77+0.53%19:59 EDT
Volume:4.82M
Turnover:4.38B
Market Cap:857.18B
PE:39.51
High:925.38
Open:910.55
Low:899.29
Close:917.50
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:1.54
T/O Rate:0.51%
Dividend:6.00
Dividend Rate:0.66%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:32.30
PE(LYR):39.51

Loading ...

Eli Lilly & Co Slides as Bold Pipeline Tested

TIPRANKS
·
Yesterday

Eli Lilly CEO David Ricks' pay rises 26% for 2025

Reuters
·
Yesterday

Eli Lilly & Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Yesterday

Eli Lilly Says CEO David a. Ricks's 2025 Total Compensation Was $36.7 Mln - SEC Filing

THOMSON REUTERS
·
Yesterday

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires Live
·
Yesterday

Eli Lilly Advances Digital Sleep Tech Study in Early Alzheimer’s Tracking

TIPRANKS
·
Yesterday

Eli Lilly’s New Diabetes Candidate LY3549492 Advances With Completion of Early-Stage Study in Japan

TIPRANKS
·
Yesterday

BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
Mar 20

Market Chatter: Eli Lilly Alzheimer's Drug to be Reconsidered by UK Health Regulator

MT Newswires Live
·
Mar 20

Eli Lilly Wins Appeal for Alzheimer's Drug, Prompting NHS Review of Coverage

Stock News
·
Mar 20

Health Rounds: Diabetes patients who stop GLP-1 drugs increase their heart risks

Reuters
·
Mar 20

Eli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis

TIPRANKS
·
Mar 20

US FDA approves higher dose of Novo's Wegovy under new fast-track review program

Reuters
·
Mar 20

Eli Lilly data compare favorably to Mounjaro, Ozempic, says Deutsche Bank

TIPRANKS
·
Mar 19

Eli Lilly retatrutide results ‘favorable,’ but similar to Mounjaro, says Truist

TIPRANKS
·
Mar 19

Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News

TIPRANKS
·
Mar 19

Eli Lilly's 'Triple Agonist' Is More Than Just a Weight-Loss Drug. This Trial Proves It. -- Barrons.com

Dow Jones
·
Mar 19

Lilly's Retatrutide Slashes Both Weight Loss and Blood Sugar Levels in Landmark Study -- Update

Dow Jones
·
Mar 19

Lilly Phase 3 TRANSCEND-T2D-1 trial shows retatrutide cuts A1C up to 2% and weight 16.8%

Reuters
·
Mar 19

Lilly's Triple Agonist, Retatrutide, Demonstrated Significant Reductions in a1c and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes

THOMSON REUTERS
·
Mar 19